Billy Lu

Billy Lu

Auto-generated profile, based on publicly available information

Billy Lu

Department of Pharmacology, Weill Cornell Medicine, New York, New York. 2

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
RSRyan N. Serio
Ryan N. Serio
ASArmin Scheben
Armin Scheben
BLBilly Lu
Billy Lu
DGDomenic V. Gargiulo
Domenic V. Gargiulo
LPLucrezia Patruno
Lucrezia Patruno
DNDawid G. Nowak
Dawid G. Nowak
The patterns by which primary tumors spread to metastatic sites remain poorly understood. Here, we define patterns of metastatic seeding in prostate cancer using a novel injection-based mouse model—EvoCaP (Evolution in Cancer of the Prostate), featuring aggressive metastatic cancer to bone, liver, lungs, and lymph nodes. To define migration histories between primary and metastatic sites, we used our EvoTraceR pipeline to track distinct tumor clones containing recordable barcodes. We detected widespread intratumoral heterogeneity from the primary tumor in metastatic seeding, with few clonal populations instigating most migration. Metastasis-to-metastasis seeding was uncommon, as most cells remained confined within the tissue. Migration patterns in our model were congruent with human prostate cancer seeding topologies. Our findings support the view of metastatic prostate cancer as a systemic disease driven by waves of aggressive clones expanding their niche, infrequently overcoming constraints that otherwise keep them confined in the primary or metastatic site. Significance: Defining the kinetics of prostate cancer metastasis is critical for developing novel therapeutic strategies. This study uses CRISPR/Cas9-based barcoding technology to accurately define tumor clonal patterns and routes of migration in a novel somatically engineered mouse model (EvoCaP) that recapitulates human prostate cancer using an in-house developed analytical pipeline (EvoTraceR).

17 June 2026
Verified
Other
Open access
RSRyan N. Serio
Ryan N. Serio
ASArmin Scheben
Armin Scheben
BLBilly Lu
Billy Lu
DGDomenic V. Gargiulo
Domenic V. Gargiulo
LPLucrezia Patruno
Lucrezia Patruno
DNDawid G. Nowak
Dawid G. Nowak
Supplementary Figure S5. Immunostaining of tissues excised from prostate tumor regions.

17 June 2026
Verified
Other
Open access
RSRyan N. Serio
Ryan N. Serio
ASArmin Scheben
Armin Scheben
BLBilly Lu
Billy Lu
DGDomenic V. Gargiulo
Domenic V. Gargiulo
LPLucrezia Patruno
Lucrezia Patruno
DNDawid G. Nowak
Dawid G. Nowak
Supplementary Figure S1. Validation of EvoCaP platform in vitro. Supplementary Figure S2. BC10 exhibited robust editing efficiency in vitro. Supplementary Figure S3. Technical markers to identify tumor cells are present in organs. Supplementary Figure S4. Consistent bioluminescence and fluorescence imaging of tissues from EvoCaP mice.

17 June 2026
Verified
Other
Open access
RSRyan N. Serio
Ryan N. Serio
ASArmin Scheben
Armin Scheben
BLBilly Lu
Billy Lu
DGDomenic V. Gargiulo
Domenic V. Gargiulo
LPLucrezia Patruno
Lucrezia Patruno
DNDawid G. Nowak
Dawid G. Nowak
The patterns by which primary tumors spread to metastatic sites remain poorly understood. Here, we define patterns of metastatic seeding in prostate cancer using a novel injection-based mouse model—EvoCaP (Evolution in Cancer of the Prostate), featuring aggressive metastatic cancer to bone, liver, lungs, and lymph nodes. To define migration histories between primary and metastatic sites, we used our EvoTraceR pipeline to track distinct tumor clones containing recordable barcodes. We detected widespread intratumoral heterogeneity from the primary tumor in metastatic seeding, with few clonal populations instigating most migration. Metastasis-to-metastasis seeding was uncommon, as most cells remained confined within the tissue. Migration patterns in our model were congruent with human prostate cancer seeding topologies. Our findings support the view of metastatic prostate cancer as a systemic disease driven by waves of aggressive clones expanding their niche, infrequently overcoming constraints that otherwise keep them confined in the primary or metastatic site.Significance:Defining the kinetics of prostate cancer metastasis is critical for developing novel therapeutic strategies. This study uses CRISPR/Cas9-based barcoding technology to accurately define tumor clonal patterns and routes of migration in a novel somatically engineered mouse model (EvoCaP) that recapitulates human prostate cancer using an in-house developed analytical pipeline (EvoTraceR).

17 June 2026
Verified
Other
Open access
PDF file
RSRyan N. Serio
Ryan N. Serio
ASArmin Scheben
Armin Scheben
BLBilly Lu
Billy Lu
DGDomenic V. Gargiulo
Domenic V. Gargiulo
LPLucrezia Patruno
Lucrezia Patruno
DNDawid G. Nowak
Dawid G. Nowak
Supplementary Figure S6. Barcode design and analysis. Supplementary Figure S7. Analysis and simulation barcode data to evaluate EvoTraceR performance. Supplementary Figure S8. Pipeline for detecting and calling edits in barcode. Supplementary Figure S9. Temporal accumulation of barcode edits in vivo. Supplementary Figure S10. Eco-statistical analysis of MMUS1495. Supplementary Figure S11. Metastatic trajectories for EvoCaP mouse cohorts. Supplementary Figure S12. Organ diversity between EvoCaP mice. Supplementary Figure S13. Expansion of EvoCaP platform in vitro.

4 October 2024
Verified
Other
Open access
PDF file
RSRyan N. Serio
Ryan N. Serio
ASArmin Scheben
Armin Scheben
BLBilly Lu
Billy Lu
DGDomenic V. Gargiulo
Domenic V. Gargiulo
LPLucrezia Patruno
Lucrezia Patruno
DNDawid G. Nowak
Dawid G. Nowak
Supplementary Figure S1. Validation of EvoCaP platform in vitro. Supplementary Figure S2. BC10 exhibited robust editing efficiency in vitro. Supplementary Figure S3. Technical markers to identify tumor cells are present in organs. Supplementary Figure S4. Consistent bioluminescence and fluorescence imaging of tissues from EvoCaP mice.